Mereo BioPharma Group plc
MREO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.28
KIRA · Stoqly’s AI analyst, in plain words
- Mereo BioPharma Group plc had $0.5M of revenue in fiscal 2025.
- Its operating margin was −8,021.4%: of every 100 in sales, about −8,021 is left after running the business.
- Mereo BioPharma Group plc lost $41.9M in fiscal 2025.
- Free cash flow was −$31.0M in fiscal 2025, −6,198.2% of revenue.
Market cap
$226M
P/E
—
Revenue
$0.5M
Net income
−$41.9M
Free cash flow
−$31.0M
Operating margin
−8,021.4%
Mereo BioPharma Group plc in 30 seconds · fiscal 2025
Does it make a profit?
−8,375.6%
No. It lost money last year.
Does profit turn into cash?
−6,198.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Mereo BioPharma Group plc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- Mereo BioPharma Group plc
- CIK
- 0001719714
Mereo BioPharma Group plc · MREO
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $0.0M | $10.0M | $0.0M | $0.5M |
| Revenue growth | — | — | −100.0% | — |
| Operating margin | — | −284.2% | — | −8,021.4% |
| Net income | −$42.2M | −$29.5M | −$43.3M | −$41.9M |
| Net margin | — | −294.7% | — | −8,375.6% |
| Diluted EPS | −$0.07 | −$0.04 | −$0.06 | −$0.05 |
| Cash | ||||
| Cash from operations | −$48.8M | −$21.1M | −$32.8M | −$31.0M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$48.8M | −$21.1M | −$32.8M | −$31.0M |
| FCF margin | — | −211.3% | — | −6,198.2% |
| Share count change | — | 9.3% | 12.2% | 7.8% |
| Debt and strength | ||||
| Cash and short-term investments | $68.2M | $57.4M | $69.8M | $41.0M |
| Shareholders' equity | $51.4M | $50.5M | $61.0M | $40.9M |
| Current ratio | 3.1x | 6.7x | 5.4x | 10.5x |
| Interest coverage | −13.0x | −9.9x | −34.6x | −157.3x |
| Returns and quality | ||||
| Return on equity | −82.1% | −57.8% | −77.6% | −82.2% |
| Return on tangible equity | −82.1% | −59.6% | −71.7% | −103.7% |
| Piotroski F-score | — | 4 | 1 | 3 |
| Altman Z'' | −15.4 | −14.8 | −14.5 | −27.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Mereo BioPharma Group plc · MREO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.28 a share, the company is worth $226M.
Source: SEC EDGAR XBRL filings (CIK 0001719714). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.